FdaApplication
NDA 217026
Identifiers
- fda_app_no: NDA217026
Properties
| Property | Value |
|---|---|
| applicant_name | ACADIA PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2023-03-10 |
Revenue by product
DAYBUE
| Period | Revenue |
|---|---|
| Q2 2026 | $124.8M |
| Q1 2026 | $101.1M |
| Q4 2025 | $109.6M |
| Q3 2025 | $101.1M |
| Q2 2025 | $96.1M |
| Q1 2025 | $84.6M |
| Q4 2024 | $96.7M |
| Q3 2024 | $91.2M |
| Q2 2024 | $84.6M |
| Q1 2024 | $75.9M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| DAYBUE | TROFINETIDE | 200MG/ML | SOLUTION;ORAL |
1 product